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Abstract
Background: COPD is currently the fourth cause of morbidity and mortality in the developed world. Patients
with COPD experience a progressive deterioration and disability, which lead to a worsening in their health-
related quality of life (HRQoL). The aim of this work is to assess the Health-Related Quality of Life (HRQoL) of
patients with stable COPD followed in primary care and to identify possible predictors of disease.
Methods: It is a multicenter, epidemiological, observational, descriptive study. Subjects of both sexes, older than
40 years and diagnosed of COPD at least 12 months before starting the study were included. Sociodemographic
data, severity of disease, comorbidity, and use of health resources in the previous 12 months were collected. All
patients were administered a generic quality-of-life questionnaire, the SF-12, that enables to calculate two scores,
the physical (PCS-12) and the mental (MCS-12) component summary scores.
Results: 10,711 patients were evaluated (75.6% men, 24.4% women), with a mean age of 67.1 years (SD 9.66).
The mean value of FEV1 was 35.9 ± 10.0%. Mean PCS-12 and MCS-12 scores were 36.0 ± 9.9 and 48.3 ± 10.9,
respectively. Compared to the reference population, patients with COPD had a reduction of PCS-12, even in mild
stages of the disease. The correlation with FEV1 was higher for PCS-12 (r = 0.38) than for MCS-12 (r = 0.12).
Predictors for both HRQoL components were sex, FEV1, use of oxygen therapy, and number of visits to
emergency rooms and hospital admissions. Other independent predictors of PCS-12 were age, body mass index
and educational level.
Conclusion: Patients with stable COPD show a reduction of their HRQoL, even in mild stages of the disease.
The factors determining the HRQoL include sex, FEV1, use of oxygen therapy, and number of visits to emergency
rooms and hospital admissions.
Published: 23 May 2006
Health and Quality of Life Outcomes 2006, 4:31 doi:10.1186/1477-7525-4-31
Received: 09 March 2006
Accepted: 23 May 2006
This article is available from: http://www.hqlo.com/content/4/1/31
© 2006 Garrido et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Health and Quality of Life Outcomes 2006, 4:31 http://www.hqlo.com/content/4/1/31
Page 2 of 9
(page number not for citation purposes)
Background
Chronic obstructive pulmonary disease (COPD) is charac-
terized by the presence of a limitation to airflow that is not
completely reversible and is associated with an abnormal
inflammatory response to gases or inhaled toxic particles,
mainly tobacco [1,2]. COPD is currently the fourth cause
of morbidity and mortality in the developed world [1].
The IBERPOC study, carried out in 7 different geographi-
cal areas with nearly 5000 patients, has shown that in
Spain the prevalence of COPD in the general population
aged between 40 and 69 years is 9.1%, and is a first-order
public health problem [3]. This condition originates
approximately 10–12% of primary care consultations and
35–40% of those of pneumology, and causes 35% of
definitive occupational disabilities and 7% of hospital
admissions [4].
As the condition progresses, patients with COPD experi-
ence a progressive deterioration and disability, which lead
to a worsening in their health-related quality of life
(HRQoL). However, it has been confirmed that the evalu-
ation alone of the severity of COPD, measured by the
degree of reduction of the forced expiratory volume in one
second (FEV1), does not provide sufficient information to
establish the health condition perceived by the patients.
The interest for HRQoL measurement in patients with
COPD has grown in recent years. The fact that HRQoL is
the result of the interaction of multiple physical, psycho-
logical and social factors, unique for each individual, can
justify this interest from the scientific community [5].
Each of these domains can be measured with the objective
of establishing the performance or health condition and
the subjective perception of health. The HRQoL can be
quantified through various health evaluation question-
naires, both general and specific, widely validated [6]. The
former covers a broad range of dimensions, enable the
comparison between groups of patients with different dis-
eases, and facilitate the detection of problems or unex-
pected effects [7]. One of them is the Short Form 36 (SF-
36) questionnaire [8], that has an abbreviated version (SF-
12) [9,10]. Since one of the main objectives of the treat-
ment of COPD is to improve the general health condition
[1], it is important to identify possible factors determining
the HRQoL of these patients. Some of these have been
identified previously [11]. Relationships have been
shown between HRQoL during acute exacerbation of
chronic bronchitis with post-exacerbation functional sta-
tus, hospital readmission for acute exacerbation or COPD
and mortality [12-16].
The objective of this study was to assess the HRQoL of a
group of patients with stable COPD followed in primary
care and to identify the associated determinant factors.
Methods
Design and population of the study
This study is part of the EPIDEPOC study, a multicenter,
epidemiological, observational, descriptive project, car-
ried out in the primary care setting, with the aim of esti-
mating the use of health resources and assessing the
HRQoL of patients with stable COPD.
The recruitment of patients and the calculation of sample
size correspond to that performed in the EPIDEPOC
study. For the calculation of sample size, a cluster design
was used, considering 3 types of variables: health centers,
physicians, and medical records. Finally, it was estimated
that it was necessary to include 2422 physicians, each of
whom should recruit 5 patients. The screening of patients
was performed at random by primary care physicians
from all Spanish Autonomous Communities, whose dis-
tribution was weighed based on the population distribu-
tion of the different Autonomous Communities over the
total national. The patients were recruited during a period
of three months (from 1st January to 31st March 2003).
Subjects of both sexes, aged 40 years or older and diag-
nosed of COPD at least 12 months before the start of the
study, were included. The diagnosis of the disease was per-
formed according to the criteria of the Spanish Society of
Pneumology and Chest Surgery (SEPAR) based on the
demonstration, through a forced spirometry, of a forced
expiratory volume in 1 second (FEV1) below 80% of the
reference value and a FEV1/forced vital capacity (FVC)
ratio below 0.7 after the bronchodilation test. The severity
of the disease was rated at three levels according to the
FEV1 value: mild (FEV1 60–80% of the reference value),
moderate (FEV1  40–59% of the reference value) and
severe (FEV1 below 40% of the reference value), in accord-
ance with the SEPAR criteria [17].
Individuals suffering at the time of the study a neurologi-
cal or psychiatric disease precluding measurement were
excluded. Patients with an acute worsening of their COPD
in the previous month were also excluded. An acute wors-
ening was considered to be the occurrence of an impair-
ment of the clinical condition of the patient characterized
by an increased baseline dyspnea, purulent sputum,
increased volume of sputum or any combination of these
symptoms, of acute onset, and requiring a change in the
regular medication of the patient [18].
The study was approved by the Ethics Committee of the
Foundation Hospital Alcorcón, and all patients gave their
oral consent to participate in it. All the information
obtained will be considered as confidential and disclosed
and kept following the regular safety standards (Organic
Act 15/1999, of 13 December on the Protection of per-
sonal data).Health and Quality of Life Outcomes 2006, 4:31 http://www.hqlo.com/content/4/1/31
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Assessment of the patients
A single visit was completed, collecting in all cases the
sociodemographic data, severity of the disease, comorbid-
ity, and utilization of health resources in the previous 12
months. All patients were administered the SF-12 quality
of life questionnaire, an abbreviated version of the SF-36
health questionnaire that contains 12 items [9]. These 12
items explain more than 90% of the variance of the phys-
ical and mental component scores of the SF-36. From
them two scores can be calculated, the physical (PCS-12)
and the mental (PCS-12) component summary, using a
value of 50 with a standard deviation of 10 as reference
population. In this study, the general Spanish adult pop-
ulation has been used as reference [19]. The SF-12 is
scored from 0 to 100 so that, the higher the score, the bet-
ter the health condition.
Statistical analysis
The analysis of the data was carried out through the statis-
tical package SPSS 11.0 for Windows. The qualitative var-
iables were described as frequency and percentage and the
quantitative variables as mean, standard deviation, mini-
mum and maximum. To analyze the relationship between
the qualitative variables the χ2 Pearson test was used.
ANCOVA and ANOVA models with sex, age and disease
severity as covariates were applied for between group
comparisons. Bonferroni adjustment was applied for mul-
tiple comparisons. To evaluate the correlation among the
values of the quantitative data, the Pearson's correlation
coefficient was used. Finally, a multiple regression analy-
sis was performed using as dependent variable the physi-
cal or mental component of the HRQoL and as
independent variables: age, sex, smoking, size of the hab-
itat, educational level, body mass index, FEV1, treatment
with oxygen therapy, visits to emergency rooms and hos-
pital admissions. Independent variables included in the
model were chosen from those showing significance dif-
ferences in the bivariate analysis or deemed to be poten-
tial confounders. A value of p < 0.05 was considered to be
significant.
Results
The number of physicians participating in the study was
2,377, which enabled to recruit a total of 10,711 patients
(75.6% men, 24.4% women), with a mean age of 67.1
years (SD 9.66), and a mean body mass index of 27.6
(4.0) kg/m2. Table 1 shows the sociodemographic and
clinical characteristics of the sample studied. The mean
FEV1 value was 35.9 ± 10.0%. The severity of the disease
was mild in 35.5% of the cases, moderate in 53.4%, and
severe in 11.2%. The concomitant conditions most fre-
quently detected were hypertension (47.7%), hypercho-
lesterolemia (41.3%), anxiety (22.2%), heart disease
(18.8%), gastroduodenal ulcer (17.4%), diabetes
(16.9%), and depression (12.8%). With regard to the use
of health resources in the previous year, the mean values
were: visits to primary care physician 6.66 (SD 5.71), visits
to pneumologist 1.43 (SD 1.52), visits to emergency
rooms 1.60 (SD 2.71), and hospital admissions 0.50 (SD
1.17).
The mean PCS-12 and MCS-12 scores were 36.0 ± 9.9 and
48.3 ± 10.9, respectively. As compared to the reference
population, patients with COPD had a reduction of PCS-
12, regardless of sex, age range or degree of airflow
obstruction. However, a significant decrease was only
seen in MCS-12, vs the reference population, in women
and patients with severe COPD, with no differences in this
parameter related to age (Figure 1). Figure 2 shows the
Table 1: Sociodemographic and clinical characteristics of 
patients
Characteristic (no. of patients)
Total no. of patients 10,711
Age (years) * (8665) 64.1 ± 9.7 (40; 98)
Age groups (8862)
40–54 years 963 (10.9)
55–64 years 2,249 (25.4)
65–74 years 3,669 (41.4)
>75 years 1,981 (22.4)
Sex (man) (10620) 8,030 (75.6)
Residence population (10341)
<10,000 inhabitants 3,022 (29.2)
10,000–100,000 3,449 (33.4)
>100,000 3,870 (37.4)
Educational level (9018)
No studies 1,852 (20.5)
Primary 5,111 (56.7)
Secondary 1,582 (17.5)
University 473 (5.2)
Smoking (10649)
Never 2,468 (23.2)
Ex-smoker 6,153 (57.8)
Active smoker 2,028 (19.0)
FEV1 (9963) 35.9 ± 10.0 (4;80)
COPD Severity (9963)
Mild 3,634 (35.5)
Moderate 5,471 (53,4)
Severe 1,146 (11.2)
Visits to E.R. * (9505) 1.4 ± 1.9 (0; 12)
No. of hospital admissions * (8670) 0.5 ± 0.9 (0; 11)
Oxygen therapy (10007) 1351 (13.5)
Associated comorbidity
Hypertension (9876) 4,706 (47.7)
Hypercholesterolemia 3,995 (41.3)
Diabetes (9453) 1,598 (16.9)
Heart disease (9390) 1,770 (18,8)
Ulcer (9425) 1,637 (17.4)
Depression (9333) 1,196 (12,8)
Anxiety (9397) 2,084 (19.5)
Value expressed as frequencies (percentages)
* Value expressed as mean ± standard deviation (minimum; 
maximum).Health and Quality of Life Outcomes 2006, 4:31 http://www.hqlo.com/content/4/1/31
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Relationship of quality of life to sex, age, and severity of COPD Figure 1
Relationship of quality of life to sex, age, and severity of COPD.
Physical Component  Mental Component 
A
35
40
45
50
55
Man Woman
Control COPD
p<0.001
p<0.001
B
40,0
42,5
45,0
47,5
50,0
52,5
55,0
Man Woman
Control COPD
p<0.001
p<0.001
C
25
30
35
40
45
50
55
40-54 55-64 65-74 >=75
Age (years)
Control COPD
p<0.001
p<0.001
p<0.001
p<0.001
D
40
45
50
55
45-54 55-64 65-74 >=75
Age (years)
Control COPD
p=0.267 p=0.802 p=0.931 p=0.187
E
25
30
35
40
45
50
55
Control Mild Moderate Severe
COPD Severity
p<0.001
p<0.001
p<0.001
F
40,0
42,5
45,0
47,5
50,0
52,5
55,0
Control Mild Moderate Severe
COPD Severity
p<0.001
p=0.176
p=0.685Health and Quality of Life Outcomes 2006, 4:31 http://www.hqlo.com/content/4/1/31
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relationship between quality of life, sex, and degree of air-
flow obstruction. With regard to the PCS-12, significant
differences were only detected between men and women
in patients with moderate COPD. With regard to MCS-12,
differences were found between the two sexes in patients
with mild and moderate COPD, but not in patients with
severe COPD.
The use of oxygen therapy was associated with a signifi-
cant reduction of the quality of life, in both PCS-12 and
MCS-12. Table 2 shows the distribution of the mean
scores of both parameters based on the use of oxygen ther-
apy and the variables related to utilization of health
resources.
PCS-12 was correlated positively to FEV1 (r = 0.38, p <
0,001), however the correlation with the mental compo-
nent (MCS-12) was lower (r = 0.12). Tables 3 and 4 show
the factors determining physical and mental components
of the HRQoL, respectively. The determinant factors of
MCS-12 were sex, FEV1, use of oxygen therapy, and
number of visits to emergency rooms and hospital admis-
sions. The PCS-12 was also determined by age, Body Mass
Index and educational level. Smoking was not signifi-
cantly related to any of the components of HRQoL.
Discussion
This study shows that patients with stable COPD have, as
compared to the reference population, a reduction of
PCS-12, even in the initial stages, though they only show
a reduction in MCS-12 in the most advanced phases of the
disease. The determinant factors of both components of
HRQoL include sex, FEV1, use of oxygen therapy and
number of visits to emergency rooms and hospital admis-
sions. In addition, the age, educational level and body
mass index are also variables that influence the PCS-12.
The women in our study had lower HRQoL levels than
men, both in the physical and mental component of qual-
ity of life. Several authors have reported that women usu-
ally suffer more respiratory symptoms than men [20],
which could partly justify this finding. Furthermore, it has
been demonstrated that, after adjusting for smoking,
women show a higher risk of hospital admission for
COPD than men [21].
Most previous studies have detected a mild to moderate
association between the different areas of HRQoL and the
degree of airflow obstruction [22-28]. In our study, a
higher correlation has been found with the physical vs the
mental component of HRQoL. Thus, it seems that the
effects of COPD on health are not only mediated by the
severity of the airflow limitation. For instance, it has been
shown that the health condition perceived by the patients
correlates better with the degree of dyspnea [29,30] or
with the distance walked in the walking test [31] than
with FEV1. The patients who obtain better results in these
parameters report a limitation to fulfill their activities and
the disease has less impact in their daily life.
The influence of hypoxemia and oxygen therapy on the
HRQoL of patients with COPD has been assessed in pre-
vious studies. Some of them have found no relationship
between HRQoL and the presence of respiratory failure
[32,33]. On the contrary, we have observed that the use of
oxygen therapy is a predictive factor independent from the
Relationship between quality of life, sex, and degree of airflow obstruction Figure 2
Relationship between quality of life, sex, and degree of airflow obstruction.
Physical Component  Mental Component 
A
25
30
35
40
45
50
55
Control Mild Moderate Severe
COPD Severity
Man Woman
p=0.003 p=0,081 p<0,001 p=0,103
B
35
40
45
50
55
Control Mild Moderate Severe
COPD Severity
Man Woman
p<0.001 p<0.001 p<0.001 p=0.156Health and Quality of Life Outcomes 2006, 4:31 http://www.hqlo.com/content/4/1/31
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health condition perceived by the patients. Similar results
have been obtained in other studies. Thus, Okubadejo et
al. [34] demonstrated, through a multivariate model, the
existence of a relationship between HRQoL and the sever-
ity of hypoxemia. More recently, Ferreira et al. [35] have
also demonstrated a marked worsening of HRQoL in
patients with COPD receiving long-term oxygen therapy,
with greater influence on physical and social function
dimensions. Several reasons have been proposed to justify
the trend of the patients to reject the treatment with oxy-
gen therapy. These include the negative expectation linked
to the use of an apparatus for long time periods to main-
tain health, the noise caused by the device, the mobility
restriction resulting of its use, and the limitation involved
by the fact that the patient must be confined at home most
of the time [33,36,37].
Acute worsening is a common adverse event in the natural
history of patients with COPD. It is the most common rea-
son for medical visits, hospital admissions, and death in
these patients [38]. Furthermore, there is an increasing
evidence of the impact of these events on the health con-
dition of patients with COPD. Thus, it has shown that
patients suffering more than three annual acute worsen-
ing of COPD had a significantly greater impairment in
their quality of life than those with a lower number of
acute worsening [39,40]. Furthermore, Fan et al. [41] have
shown that HRQoL is a predictive factor independent
from hospitalization and mortality in these patients. In
our study it has been also detected that the visits to emer-
gency rooms and hospital admissions for acute worsening
of the disease in the last year influence significantly the
quality of life of patients with COPD, affecting both the
physical and mental component.
The influence of age on HRQoL in patients with COPD is
controversial. Some studies have detected no association
between the two parameters [42] and others have demon-
strated it through a logistic regression analysis that is an
independent factor [23,43]. In our study we have only
found a relationship with the physical component of
quality of life, but not with the mental. The same has hap-
pened with other parameters such as the educational level
of the patients evaluated. It is possible that subjects with a
higher educational level have a greater purchasing power
and have more material resources and, on the contrary,
those with a lower level belong to the most disadvantaged
classes, complaining later of health problems, have a
higher environmental exposure, and the percentage of
smokers among them is higher [43].
Table 2: Physical (PCS-12) and mental (MCS-12) component summaries related to the use of oxygen therapy and the utilization of 
health resources in the past year
No. of cases PCS-12 MCS-12
Oxygen therapy:
No 3,131 (84.8%) 32.4 (31.3; 33.5) 45.8 (44.4; 47.2)
Yes 562 (15.2%) 30.3 (29.1; 31.6) 43.7 (42.1; 45.3)
P 0.019 0.049
No of visits to primary care:
1 to 5 1,941 (52.3%) 32.9 (31.3; 34.5) 46.4 (44.3; 48.4)
5 to 10 1,140 (30.9%) 31.0 (29.5; 32.4) 44.2 (42.3;46.0)
Over 10 612 (16.6%) 31.0 (29.7; 32.3) 44.6 (42.9; 46.2)
P 0.130 0.241
No. of visits to pneumology:
None 883 (23.9%) 32.8 (30.9; 34.8) 48.7 (46.2; 51.1)
1 to 4 2,711 (73.4%) 31.1 (30.3; 32.0) 44.7 (43.6; 45.8)
Over 4 99 (2.7%) 31.0 (28.9; 33.1) 41.6 (38.9; 44.2)
P 0.277 0,000
No. of visits to E.R.:
None 1,481 (40.1%) 34.8 (32.7; 36.9) 48.2 (45.5; 50.8)
1 to 2 1,508 (40.8%) 31.5 (30.0; 33.1) 45.6 (43.6; 47.6)
3 to 4 466 (12.6%) 30.2 (28.8; 31.7) 45.0 (43.2; 46.8)
Over 4 238 (6.4%) 30.9 (29.2; 32.7) 41.8 (39.6; 44.0)
P 0.004 0.003
No. of hospital admissions:
None 2,544 (68.9%) 33.7 (32.5;35.0) 47.4 (45.8; 49.0)
1 755 (20.4%) 32.1 (30.5; 33.7) 43.1 (41.1; 45.1)
2 257 (7.0%) 29.2 (27.4; 31.1) 44.3 (42.1; 46.6)
Over 2 137 (3.7%) 29.5 (27.2; 31.7) 43.8 (41.0; 46.6)
P 0.000 0.006
Variables expressed as mean (95% CI).Health and Quality of Life Outcomes 2006, 4:31 http://www.hqlo.com/content/4/1/31
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There is no agreement on the relationship between BMI
and HRQoL. There seems to be an association between a
poor nutritional status and quality of life worsening in
patients with COPD, particularly those with emphysema
[44]. Our results confirm that there is an association,
though it is only demonstrated with the mental compo-
nent of quality of life. The same has happened in another
recent study, which only found a relationship with emo-
tional function, though it was weak [43]. On the contrary,
other authors have not evidenced any influence of body-
weight on the HRQoL of the patients with COPD [29,45].
Some limitations may have influenced the results of this
study. First, we have used a generic questionnaire to meas-
ure HRQoL, less sensitive than the specific tools. How-
ever, the large sample size of our study enables to
compensate this effect and give validity to our model. Sec-
ond, all the patients were from primary care, so the results
may not be extrapolable to all patients with COPD. How-
ever, a recent study evaluating this has found no relation-
ship between HRQoL and the healthcare level [29].
In conclusion, the HRQoL of the patients with COPD is in
part related to some parameters, including sex, airflow
limitation, use of oxygen therapy and number of acute
worsening and hospital admissions. However, these fac-
tors do not predict overall the high variability of HRQoL.
Despite this, their measurement enables to identify the
patients with a greater disability and enhances the assess-
ment of the effects of various interventions on a standard
basis.
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Table 3: Coefficients of the multiple linear regression equation for the final physical component of quality of life
Independent variables Coefficients (95% CI) Standard coefficients Sig.
Constant 48.6 (44,8; 52,3) <0.001
Age -0.25 (-0.28; -0.27) -0.233 <0.001
Sex -1.21 (-1.91; -0.51) -0.050 0.001
Educational level 1.22 (0,82; 1,62) 0.092 <0.001
FEV1 0.019 (0,16; 0,26) 0.226 <0.001
Oxygen therapy -2.84 (-3.75; -1.93) -0.101 <0.001
Body Mass Index -0.17 (-0.24; -0.10) -0.068 <0.001
≤ 2 visits to E.R. -0.84 (-1.02; -0.66) -0.162 <0.001
≤ 2 hospital admissions -0.93 (-1.31; -0.54) -0.086 <0.001
R2 = 0.31
Dependent variable: final physical component.
Variables excluded: size of the habitat, smoking
Table 4: Coefficients of the multiple linear regression equation for the final mental component of quality of life
Independent variables Coefficients (95% CI) Standard coefficients Sig.
Constant 52.6 (50.5; 54.8) <0.001
Sex -5.71 (-6.57; -4.84) -0.21 <0.001
FEV1 0.08 (0.04; 0.11) 0.09 <0.001
Oxygen therapy -2.25 (-3.38; -1.13) -0.07 <0.001
≤ 2 visits to E.R. -0.63 (-0.86; -0.40) -0.11 <0.001
≤ 2 hospital admissions -1.01 (-1.49; -0.53) -0.09 <0.001
R2 = 0.11
Dependent variable: final mental component.
Variables excluded: size of the habitat, age, smoking, educational level, Body Mass Index.Health and Quality of Life Outcomes 2006, 4:31 http://www.hqlo.com/content/4/1/31
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